Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Carasent AB (publ)'s annualized net income for the quarter that ended in Jun. 2026 was kr-11.1 Mil. Carasent AB (publ)'s average shareholder tangible equity for the quarter that ended in Jun. 2026 was kr30.2 Mil. Therefore, Carasent AB (publ)'s annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was -36.82%.
The historical rank and industry rank for Carasent AB (publ)'s Return-on-Tangible-Equity or its related term are showing as below:
LTS:0H9M'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -53.53 Med: -0.03 Max: 858.14
Current: 45.28
During the past 13 years, Carasent AB (publ)'s highest Return-on-Tangible-Equity was 858.14%. The lowest was -53.53%. And the median was -0.03%.
LTS:0H9M's Return-on-Tangible-Equity is ranked better than 81.25% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.17
vs LTS:0H9M: 45.28
Carasent AB (publ) (LTS:0H9M) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Carasent AB (publ) Return-on-Tangible-Equity Related Terms
Carasent AB (publ) Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carasent AB (publ) Return-on-Tangible-Equity Chart
LTS:0H9M vs VEEV, BTSG, TEM: Return-on-Tangible-Equity Comparison
For the Health Information Services subindustry, Carasent AB (publ)'s Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -36.82% mean?
Carasent AB (publ) (LTS:0H9M) has a Return-on-Tangible-Equity of -36.82% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Carasent AB (publ) and its competitors. According to the industry distribution chart, Carasent AB (publ) ranks #108 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 18.7%.
Is Carasent AB (publ)'s Return-on-Tangible-Equity too high?
Carasent AB (publ)'s current Return-on-Tangible-Equity is -36.82%. Based on the distribution chart, Carasent AB (publ) ranks #108 out of 576 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s Return-on-Tangible-Equity compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #108 out of 576 companies for Return-on-Tangible-Equity. This places Carasent AB (publ) in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.17, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current Return-on-Tangible-Equity is -36.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (LTS:0H9M) has a current Return-on-Tangible-Equity of -36.82%. The stock's GF Value™ is kr24.22, compared to a current price of kr20.60 — trading 14.9% below its estimated fair value. The current Return-on-Tangible-Equity is -36.82%. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Carasent AB (publ) (LTS:0H9M), the current Return-on-Tangible-Equity is -36.82% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (LTS:0H9M) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of kr20.60 is trading 14.9% below its estimated GF Value™ of kr24.22.
Key valuation signals for LTS:0H9M:
Return-on-Tangible-Equity: -36.82%
GF Value™: kr24.22 vs. price of kr20.60 (14.9% below fair value)
No single metric tells the full story. See the LTS:0H9M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score
Get the complete analysis for LTS:0H9M
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H9M has been successfully added to your 
